Navigation Links
Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million,Annually

should request testing if they suspect they are at risk."

Fortunately, trich can be cured with a one-day, one-dose regimen of Tindamax(R) (tinidazole). Tindamax(R) is administered orally in a single 2- gram dose, and has demonstrated cure rates of 92 to 100 percent. In addition, Tindamax(R) is recognized as one of the drugs of choice for the treatment of trichomoniasis in the recently issued 2006 Sexually Transmitted Diseases Treatment Guidelines (www.cdc.gov/std/treatment) from the Centers for Disease Control and Prevention (CDC).

Sexual partners should be treated simultaneously for maximum efficacy and prevention of re-infection. More information on Tindamax(R) and trichomoniasis is available at http://www.tindamax.com.

About Tindamax(R)

Tindamax(R), a second-generation 5-nitroimidazole compound, is indicated in the United States for the treatment of trichomoniasis, the intestinal infections giardiasis and intestinal amebiasis, and amebic liver abscess. It has been approved for use in the United States since May 2004 and is recognized as one of the drugs of choice for the treatment of trichomoniasis by the Centers for Disease Control and Prevention (CDC).

Full prescribing information for Tindamax(R), as well as information about trichomoniasis, is available at http://www.tindamax.com.

About Mission Pharmacal

Mission Pharmacal, the maker of Citracal(R), is a family-owned pharmaceutical company based in San Antonio, Texas. For more than 60 years, the company has been dedicated to identifying unmet health needs in the marketplace and developing innovative prescription and over-the-counter products to meet them. Currently, Mission Pharmacal provides physicians and consumers with pharmaceutical, nutritional and diagnostic products. For more informa
'"/>




Page: 1 2 3

Related medicine technology :

1. Common Preterm Labor Drug Has More Side Effects Than Alternative, Finds Study from Packard Childrens Hospital and Stanford
2. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
3. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
4. Blood Levels of Paliperidone Extended-Release Tablets are Not Increased by Common Antidepressant
5. Researchers Discover a Common Variation in a Gene Segment that Increases the Risk for Prostate Cancer
6. One-Third of Patients Discontinue Common Breast Cancer Therapy

Post Your Comments:
(Date:12/1/2009)... -- Reportlinker.com announces that a new market r..., The Future of Oncology Therapeutics - Market Fo... Pipeline and Deals Analysis ,, http://www.re...rapeutics---Market-Forecasts-to-2015-Competitive-B...ml ,, Summary ,, The author has released ...
(Date:12/1/2009)...ation reduction in cardiac CT scans ,, CHICAGO,..., a radiologist from Fairfax Radiological Consulta...findings of a study that shows a 90 percent reduct...ived from CT scans compared to scans performed two...dy to the annual meeting of the Radiological Socie...
(Date:12/1/2009)...c. 1 Former New Jersey A...ted when his radiotherapy treatment sessions for p... to less than five. Midway through his course of ... Cancer Center acquired the region,s first Rapi...dical Systems (NYSE: VAR ), making it possible f...
Breaking Medicine Technology:Reportlinker Adds The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Reportlinker Adds The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Radiation Reduction in Heart CT Scans Reported in Study 2Fighting Prostate Cancer With Speed and Accuracy: RapidArc(R) Radiotherapy Available at the Delaware Valley Urology Cancer Treatment Center 2Fighting Prostate Cancer With Speed and Accuracy: RapidArc(R) Radiotherapy Available at the Delaware Valley Urology Cancer Treatment Center 3Fighting Prostate Cancer With Speed and Accuracy: RapidArc(R) Radiotherapy Available at the Delaware Valley Urology Cancer Treatment Center 4Fighting Prostate Cancer With Speed and Accuracy: RapidArc(R) Radiotherapy Available at the Delaware Valley Urology Cancer Treatment Center 5Many Health Care Workers May Shun Swine Flu Shot 55387 1Many Health Care Workers May Shun Swine Flu Shot 55387 2Danaher to Present at Morgan Stanley Global Industrials Conference 55383 1Waste Management and Terrabon Announce Investment Agreement for Waste To Fuel Conversion Technology 13694 1Waste Management and Terrabon Announce Investment Agreement for Waste To Fuel Conversion Technology 13694 2Waste Management and Terrabon Announce Investment Agreement for Waste To Fuel Conversion Technology 13694 3Waste Management and Terrabon Announce Investment Agreement for Waste To Fuel Conversion Technology 13694 4
...for PTC124 - , , SOUTH PLAINFIELD, N.J., Feb. 3 ...it has successfully completed patient enrollment o... with nonsense mutation Duchenne and Becker muscul...wo months ahead of schedule. The company also ann...ic name, ataluren. , , (Logo: http://www.newsco...
...3 Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) t...hip discussions regarding R788 until after results...ilable. The company expects that,these results, ...ill,substantially further the understanding of R78...nomics in a possible deal. The company expects to ...
Other Medicine Technology:PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy 2PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy 3PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy 4PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy 5Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results 2Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results 3Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results 4Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results 5
(Date:12/2/2009)...nical trial presented today at the annual meeting ...) provide the first strong evidence of the benefit...se breasts who are at elevated risk for breast can...highly sensitive in depicting early breast cancer....nd in addition to mammography significantly improv...
(Date:12/1/2009)...st Medical Center in Oak Lawn, Ill. has become the... the first for Chicago’s south and southwest...l’s plans today (December 1) by the Illinois... Springfield, Ill. (Vocus) -...l. has become the state’s newest kidney tran...
(Date:12/1/2009)...ewswire/ -- Reportlinker.com announces that a new ...ue: ,, The Future of Central Nervous System Di...mpetitive Benchmarking, Product Pipeline and Deals...6814/The-Future-of-Central-Nervous-System-Diseases...ve-Benchmarking-Product-Pipeline-and-Deals-Analysi...
(Date:12/1/2009)...Newswire/ -- Reportlinker.com announces that a new...gue: ,, The Future of Monoclonal Antibodies - ..., Product Pipeline and Deals Analysis ,, http...oclonal-Antibodies---Market-Forecasts-to-2015-Comp...alysis.html ,, Summary ,, The author has...
(Date:12/1/2009)...re-USNewswire/ -- The Kerlan Jobe Orthopaedic Clin...greed to pay the United States $3 million to settl...rom HealthSouth Corporation, the Justice Departmen...ves allegations that HealthSouth paid kickbacks to...onations to the Kerlan Jobe Foundation, loan forgi...
Breaking Medicine News(10 mins):Health News:Annual screening with breast ultrasound or MRI could benefit some women 2Health News:State Approves Plans For Kidney Transplants At Advocate Christ Medical Center 2Health News:State Approves Plans For Kidney Transplants At Advocate Christ Medical Center 3Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 13Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 14Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 15Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 16Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 17Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 18Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 19Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 20Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 21Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 22Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12
...wledge that humans and other animals are able to v...he brain compares the images from each. But we can...s have been searching for how the brain accomplish...processes both the image from a single eye and als...
...m supported by the National Institutes of Health (... and Infectious Diseases (NIAID) has identified ch...erapies for schistosomiasis, a parasitic disease t.... , In their paper, researchers from Illinois Sta...
...est Prospective Trial to Examine Asthma Outcomes B..., RESEARCH TRIANGLE PARK, N.C. and PHILADELPHIA, ...showed that genetic differences at,the site of the...alation powder) or Serevent Diskus(R) (salmeterol ...
...0 cities waive co-pays if diabetic is "coached" by...y News) -- Diabetics taking part in the Diabetes T...y clinical and satisfaction indicators in the earl...ployer-based diabetes self-management program that...
... tumors from gaining a blood supply, studies sugge... -- The drug dopamine -- currently used to treat p...e, pituitary tumors and heart attack -- may also p...ment of new blood vessels, something that would sl...
...ch 14 Eli Lilly and Company,(NYSE: LLY ) today c...ticle,flat out wrong., The Times report in questio...Company trial that is underway and attempted to,in...he company makes the following statement:, -- Th...
Other Medicine News:Health News:Researchers discover second depth-perception method in brain 2Health News:Scientists identify new leads for treating parasitic worm disease 2Health News:Scientists identify new leads for treating parasitic worm disease 3Health News:GSK Data Suggests Efficacy of Advair(R) and Serevent(R) is Not Impacted by Genetic Profile 2Health News:GSK Data Suggests Efficacy of Advair(R) and Serevent(R) is Not Impacted by Genetic Profile 3Health News:GSK Data Suggests Efficacy of Advair(R) and Serevent(R) is Not Impacted by Genetic Profile 4Health News:Self-Management Program Helps Diabetics 2Health News:Parkinson's Drug May Fight Cancer 2Health News:Statement from Eli Lilly and Company: Response to Today's New York Times Article, 'Lilly E-Mail Discussed Off-Label Drug Use' 2Health News:Statement from Eli Lilly and Company: Response to Today's New York Times Article, 'Lilly E-Mail Discussed Off-Label Drug Use' 3Health News:Statement from Eli Lilly and Company: Response to Today's New York Times Article, 'Lilly E-Mail Discussed Off-Label Drug Use' 4Health News:Statement from Eli Lilly and Company: Response to Today's New York Times Article, 'Lilly E-Mail Discussed Off-Label Drug Use' 5
LES Identification Accessories Kit
pHix Strips
...se pH catheters are efficient, economical, elimina...er patient comfort during the test period., ,NOTE...gned to use temperature correction factors that al...temperature correction factors for Bravo capsules ...
... of online quality control with Quantrol Online. I...and peer group statistics right at your fingertips... internet based format for review of quality contr...ntrol data mangement systems with long report turn...
Medicine Products: